Asenapine Maleate
The maleate salt of asenapine, formulated as a sublingual tablet or skin patch that delivers this antipsychotic by avoiding the gastrointestinal tract. It is used in the management of schizophrenia and acute manic or mixed episodes of bipolar disorder.
Молекулярная масса
401,8000 g/mol
TPSA
87,10 Ų
Терапевтические области
Механизм действия
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
2D Структура
Cite this structure
Embed this structure
SMILES
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O
InChI
InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula
C21H20ClNO5
HBD / HBA
2 / 6
Вращаемые Связи
2
Тяжёлые Атомы
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
The maleate salt of asenapine, formulated as a sublingual tablet or skin patch that delivers this antipsychotic by avoiding the gastrointestinal tract. It is used in the management of schizophrenia and acute manic or mixed episodes of bipolar disorder.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Asenapine Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3544974. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6917875. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="asenapine-maleate"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/asenapine-maleate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/asenapine-maleate/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/asenapine-maleate/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="asenapine-maleate"></drugfyi-drug>